MIRA-15 Genetic Cancer Panel

High-Throughput NGS Test for Breast, Ovarian & Hereditary Cancers

MIRA 15 is a next generation sequencing (NGS) based genetic testing panel designed for the comprehensive detection of mutations associated with breast cancer, ovarian cancer, and other hereditary cancers. The test supports precision oncology by enabling accurate identification of clinically significant variants to guide targeted therapy decisions.

Clinical Purpose & Applications

• Detection of germline and somatic genetic mutations
• Cancer risk assessment and genetic profiling
• Support for personalized and targeted cancer therapies
• Molecular oncology diagnostics and research

Key Benefits

• Comprehensive exon coverage of cancer associated genes
• High throughput and cost effective NGS workflow
• Reduced library preparation time
• Automated bioinformatics analysis via XplainBio platform
• High analytical sensitivity with low DNA input requirements

Technology Overview

• Analysis Type: Qualitative massive parallel sequencing
• Sequencing Method: Next Generation Sequencing (NGS)
• Target Enrichment: Multiplex PCR
• Read Length: 2 × 150 bp

Sample & Compatibility

• Sample Types: Peripheral blood, FFPE tissue
• Recommended DNA Input: 20 ng
• Compatible Platforms: Illumina, GeneMind, Salus, MGI

Technical Specifications

Parameter	Specification
Number of Reactions	96 / 48
Analytical Sensitivity	300 gene copies per 1 µL DNA
Coverage Uniformity	95%
Average Library Length	320 bp
Required Reads	400,000 (germline) / 900,000 (somatic)
Library Prep Time (96 samples)	~8.5 hours
Manual Work Time	~4.5 hours

Workflow Stages

1. Target multiplex PCR
2. Amplicon purification
3. Index PCR
4. Library synthesis
5. Library pooling and purification
6. NGS sequencing
7. Automated data interpretation

Kit Configurations

• MIRA-15-96A
• MIRA-15-96B
• MIRA-15-96AM
• MIRA-15-48AM

Data Interpretation

MIRA-15 integrates with the XplainBio automated bioinformatics platform, enabling rapid variant interpretation, simplified reporting, and reduced manual analysis time.

Intended Users

• Molecular diagnostic laboratories
• Oncology hospitals and cancer centers
• Genetic testing laboratories
• Research institutions

Important Notes

• For professional in-vitro diagnostic use only
• Results must be interpreted by qualified healthcare professionals
• Genetic findings should be correlated with clinical data
• This test is a screening and diagnostic support tool